Healthcare
Actavia Life Sciences, Inc.(RASP)
Live Price
Offline$0.0005
+0.00% today
1Y Change
-87.50%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +23.0%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Actavia Life Sciences, Inc. (RASP) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 87.5% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +23.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +23.0%, free cash flow +97.3% with operating margin 0.0% and ROIC 242.9%. Stock Foundry combines RASP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on Jun 23, 2025, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +23.0%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Jun 23, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 May 30, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Feb 28, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RASP
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RASP Max Drawdown
-87.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RASP and SPY.
Company Overview
Actavia Life Sciences, Inc.
Other OTC
Actavia Life Sciences, Inc. is a biotechnology company, which engages in the development of therapeutics for the treatment of leukemia and lymphoma diseases. It also develops small molecule drug candidates that focus on treating acute myeloid leukemia. The company was founded in 2013 and is headquartered in New York, NY.
- Leadership
- Keeren Shah
- IPO Date
- Feb 24, 2015
- Employees
- 1
- Street Address
- 420 Lexington Avenue
- Mailing
- New York City, NY, 10170
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 646 396 4087
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +23.0%
- Free Cash Flow
- +97.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 243.8%
- ROIC
- 242.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.05
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.